# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 22, 2023

Date of Report (Date of earliest event reported)

### **Zura Bio Limited**

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands	001-40598	98-1725736
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
1489 W. Warm Springs Rd. #11 Henderson, Nevada		89014
(Address of Principal Executive Offi	ices)	(Zip Code)
Registrant's	s telephone number, including area code: (702)	757-6133
(Former	N/A name or former address, if changed since last	report)
Check the appropriate box below if the Form 8-K fil following provisions:	ling is intended to simultaneously satisfy the	filing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425 under the Securities Act		
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act		
☐ Pre-commencement communications pursuant to R	tule 14d-2(b) under the Exchange Act	
☐ Pre-commencement communications pursuant to R	tule 13e-4(c) under the Exchange Act	
Securities registered pursuant to Section 12(b) of the Ad	ct:	
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Ordinary Shares, par value \$0.0001 pe	r share ZURA	The Nasdaq Stock Market
Warrants, each whole warrant exercisable for one Ordinary Share at an exercise price of \$11.50 pe		The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emergian Rule 12b-2 of the Securities Exchange Act of 1934 (17		5 of the Securities Act of 1933 (17 CFR §230.405) or
Emerging growth company $\boxtimes$		
If an emerging growth company, indicate by check man or revised financial accounting standards provided pursu		stended transition period for complying with any new

## Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 31, 2023, the Board of Directors (the "Board") of the Company increased the size of the Board from seven directors to nine directors. On June 22, 2023, the Board appointed Parvinder Thiara to fill the vacancy on and serve as a member of the Board, to serve until the next annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.

Parvinder Thiara has served as a member of the Company's board of directors since June 22, 2023. Mr. Thiara founded Athanor Capital in January 2017, a New York-based hedge fund manager, and currently serves as its Chief Investment Officer. Mr. Thiara has also been serving as a member of Tourmaline Bio's board of directors since September 2022. Previously, Mr. Thiara held various roles at D.E. Shaw & Co., including most recently as a Senior Vice President. Mr. Thiara earned a B.A. degree in Chemistry from Harvard College and an M.Sc. degree in Theoretical Chemistry from Oxford University as a Rhodes Scholar. The Company believes Mr. Thiara is qualified to serve on its board of directors due to his medical and scientific background, combined with his significant experience as a manager and investor in the life sciences industry.

Mr. Thiara has no family relationships with any of the executive officers or directors of the Company. There have been no transactions in the past two years to which the Company or any of its subsidiaries was or is to be a party, in which Mr. Thiara had, or will have, a direct or indirect material interest.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 2, 2023

ZURA BIO LIMITED

By: /s/ Kim Davis
Name: Kim Davis

Title: Chief Legal Officer